Top Analyst Reports for Merck, Salesforce & Philip Morris
https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306
Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
0
NVS or LLY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2206412/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2206412
Jan 05, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
0
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605
Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
0
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205112
Jan 03, 2024 - Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
0
Arcadis NV (ARCAY) Is a Great Choice for 'Trend' Investors, Here's Why
https://www.zacks.com/stock/news/2204413/arcadis-nv-arcay-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2204413
Jan 02, 2024 - If you are looking for stocks that are well positioned to maintain their recent uptrend, Arcadis NV (ARCAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
0
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
https://www.zacks.com/stock/news/2200609/roche-s-rhhby-sbla-for-xolair-gets-fda-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200609
Dec 20, 2023 - The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
0
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
https://www.zacks.com/stock/news/2194094/novartis-nvs-gets-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194094
Dec 06, 2023 - Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
0
What Makes Wolters Kluwer NV (WTKWY) a Good Fit for 'Trend Investing'
https://www.zacks.com/stock/news/2194044/what-makes-wolters-kluwer-nv-wtkwy-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2194044
Dec 06, 2023 - Wolters Kluwer NV (WTKWY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
0